NICE approves groundbreaking one-off gene therapy for severe sickle cell disease
People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE
Related Articles
Current landscape of clinical management for systemic light chain amyloidosis
Published in Future Cardiology (Ahead of Print, 2025)
Cancer statistics, 2025
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data…
Evaluating the side effects of 2L treatment for upper gastrointestinal cancer
Timothy Brown, MD, UT Southwestern Medical Center, Dallas, TX, highlights the importance of dialogue between patients and clinicians regarding the side effects and treatment logistics…
Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A | NEJM
Severe hemophilia A is managed with factor VIII replacement or hemostatic products that stop or prevent bleeding. Data on gene therapy with hematopoietic stem-cell (HSC)–based…
Welcome! You are invited to join a webinar: IACH for Patients (French)- Dernières avancées dans le domaine du myélome multiple d’après les congrès L’ASH 2024. After registering, you will receive a confirmation email about joining the webinar.
Speakers: Arthur Bobin Titouan Cazaubiel Thomas Chalopin Bernard Delcour Laurent Gillot Mohamad Mohty Description: Rejoignez-nous pour un webinar dédié aux patients atteints de myélome et…
The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials
Acute toxicity following prostate radiotherapy was statistically significantly associated with late toxicity and with decrement in patient-reported QOL metrics. These data support efforts to evaluate…
FDA Approval: Zenocutuzumab for NRG1+ NSCLC | IASLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of zenocutuzumab for NSCLC with an NRG1 fusion. NRG1…
‘Groundbreaking’ potential cure for sickle cell in England approved for NHS use
Clinical trials find one-time gene therapy exa-cel offers ‘functional cure’ in 96.6% of patients
The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials
Acute toxicity following prostate radiotherapy was statistically significantly associated with late toxicity and with decrement in patient-reported QOL metrics. These data support efforts to evaluate…
How the PGA and NBA Can Prepare You for Your Next Medical Appointment
No one has a greater stake in your healthcare than you do.
